VanEck Associates
WST icon

VanEck Associates’s West Pharmaceutical WST Stock Holding History

VanEck Associates’s Portfolio WST Stock Details WST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$217M Sell
604,754
-108,825
-15% -$33.3M 0.13% 110
2026
Q1 		$179M Sell
713,579
-2,508
-0.4% -$624K 0.13% 137
2025
Q4 		$197M Sell
716,087
-708,792
-50% -$194M 0.16% 122
2025
Q3 		$374M Sell
1,424,879
-61,308
-4% -$14.9M 0.35% 65
2025
Q2 		$325M Buy
1,486,187
+38,339
+3% +$8.2M 0.37% 59
2025
Q1 		$324M Buy
1,447,848
+758,355
+110% +$209M 0.42% 61
2024
Q4 		$226M Buy
689,493
+676,167
+5,074% +$213M 0.29% 86
2024
Q3 		$3.82M Sell
13,326
-722
-5% -$221K ﹤0.01% 742
2024
Q2 		$4.63M Buy
14,048
+436
+3% +$154K 0.01% 608
2024
Q1 		$5.39M Buy
13,612
+2,873
+27% +$1.06M 0.01% 557
2023
Q4 		$3.78M Buy
10,739
+226
+2% +$80K 0.01% 625
2023
Q3 		$3.94M Sell
10,513
-2,405
-19% -$930K 0.01% 565
2023
Q2 		$4.94M Sell
12,918
-221
-2% -$78.9K 0.01% 517
2023
Q1 		$4.55M Buy
13,139
+330
+3% +$96.4K 0.01% 507
2022
Q4 		$3.02M Sell
12,809
-237
-2% -$56.2K 0.01% 584
2022
Q3 		$3.21M Buy
13,046
+950
+8% +$289K 0.01% 546
2022
Q2 		$3.66M Sell
12,096
-144
-1% -$46.9K 0.01% 529
2022
Q1 		$5.03M Buy
12,240
+1,360
+13% +$532K 0.01% 505
2021
Q4 		$5.1M Buy
10,880
+1,384
+15% +$596K 0.01% 506
2021
Q3 		$4.03M Buy
9,496
+417
+5% +$176K 0.01% 511
2021
Q2 		$3.26M Buy
9,079
+1,213
+15% +$401K 0.01% 547
2021
Q1 		$2.22M Buy
7,866
+882
+13% +$252K 0.01% 593
2020
Q4 		$1.98M Buy
6,984
+2,103
+43% +$590K 0.01% 546
2020
Q3 		$1.34M Buy
4,881
+1,138
+30% +$301K ﹤0.01% 575
2020
Q2 		$850K Buy
+3,743
New +$735K ﹤0.01% 648

Other funds holding WST

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
GIM
Generation Investment Management London, United Kingdom $10.3B AUM 4.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

VanEck Associates's WST Position: Q2 2026 in Review

VanEck Associates reduced its West Pharmaceutical (WST) stake by 15% in Q2 2026, selling an estimated $33.3M and leaving 604,754 shares worth $217M. The position accounts for 0.13% of the portfolio, ranked #110.

VanEck Associates first reported a position in WST in Q2 2020 and has held it in 25 quarters since. The position peaked at $374M in Q3 2025. 830 funds tracked by Wall St. Rank hold WST as of Q2 2026.

  • VanEck Associates held 604,754 shares of West Pharmaceutical worth $217M as of Q2 2026.
  • VanEck Associates sold 108,825 West Pharmaceutical shares in Q2 2026, an estimated $33.3M.
  • West Pharmaceutical made up 0.13% of VanEck Associates's portfolio in Q2 2026, its #110 holding.
  • VanEck Associates first reported a position in West Pharmaceutical in Q2 2020 and has held it in 25 quarters since.
  • VanEck Associates's West Pharmaceutical position peaked at $374M in Q3 2025.
  • 830 funds tracked by Wall St. Rank held West Pharmaceutical as of Q2 2026.

Based on VanEck Associates's 13F filing for Q2 2026, filed 14 Aug 2026.